| Identification | Back Directory | [Name]
INDEX NAME NOT YET ASSIGNED | [CAS]
2762422-55-7 | [Synonyms]
AC1-IN-1
AC1-IN-38
Adenylyl cyclase,Adenylate Cyclase,Inhibitor,AC1IN1,Chronic Pain,inhibit,antiallodynic,nontoxic,HEK293 cells,AC1 IN 1,CNS-penetration | [Molecular Formula]
C18H18FN5O2 | [MOL File]
2762422-55-7.mol | [Molecular Weight]
355.37 |
| Hazard Information | Back Directory | [Uses]
AC1-IN-1 is a potent and selective Adenylyl cyclase type 1 (AC1) inhibitor with an IC50 of 0.54 μM. AC1-IN-1 displays modest antiallodynic effects in a mouse model of inflammatory pain. AC1-IN-1 has CNS activity[1]. | [Biological Activity]
AC1-IN-1 is a potent and selective Adenylyl cyclase type 1 (AC1) inhibitor with an IC50 of 0.54 μM. AC1-IN-1 displays modest antiallodynic effects in a mouse model of inflammatory pain. AC1-IN-1 has CNS activity[1].
AC1-IN-1 (compound 38; HEK293 cells; 30 μM, 1 hours) shows nontoxic to this human cell line[1].
AC1-IN-1 (5.6 mg/kg; i.v.) displays modest, yet statistically significant, antiallodynic effects at 1 h post-treatment compared to the 0 min (allodynic) time point[1]. | [in vivo]
AC1-IN-1 (5.6 mg/kg; i.v.) displays modest, yet statistically significant, antiallodynic effects at 1 h post-treatment compared to the 0 min (allodynic) time point[1]. | Animal Model: | Male and female C57BL/6N mice (complete Freund’s adjuvant inflammatory pain model)[1] | | Dosage: | 5.6 mg/kg (dissolved in 10% DMSO/10% Cremaphor/80% saline) | | Administration: | Intravenous injection; 2 hours | | Result: | Displayed modest, yet statistically significant, antiallodynic effects. |
| [References]
[1]. Scott JA, et al. Optimization of a Pyrimidinone Series for Selective Inhibition of Ca2+/Calmodulin-Stimulated Adenylyl Cyclase 1 Activity for the Treatment of Chronic Pain. J Med Chem. 2022; 65(6):4667-4686. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|